Tech Company Financing Transactions
Trellis Bioscience Funding Round
On 7/20/2026, Trellis Bioscience raised $9 million in Series C financing from Easton Capital, New Science Ventures and AMR Action Fund.
Transaction Overview
Company Name
Announced On
7/20/2026
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to support completion its Phase 2 trial of calpurbatug (TRL1068), an investigational mAb treatment for chronic prosthetic joint infections (PJI).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
845 Oak Grove Ave. 202
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Not Recorded
Overview
Trellis Bioscience, Inc. has developed a breakthrough technology platform for discovery and selection of very rare cells that produce ideal proteins such as antibodies, selected for specificity, selectivity, affinity, secretion rate and other desired characteristics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stefan Ryser
Chief Marketing Officer
Anton Leighton
Chief Technical Officer
Stote Ellsworth
Founder
Lawrence Kauvar
VP - R & D
Mikhail Gishizky
Browse more venture capital transactions:
Prev: 7/20/2026: Sereact venture capital transaction
Next: 7/20/2026: Kuzen Co. venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs